Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature

Tumori. 2012 Sep-Oct;98(5):139e-142e. doi: 10.1177/030089161209800525.

Abstract

Sunitinib is one of the standard targeted therapies used in metastatic renal cell carcinoma. It is generally a reasonably tolerated oral systemic therapy but can be occasionally associated with life-threatening toxicities. We present a case of reversible posterior encephalopathy, which is a rare but recognised side effect of the treatment.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / adverse effects*
  • Brain / pathology*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / secondary
  • Diagnosis, Differential
  • Female
  • Headache / etiology
  • Humans
  • Indoles / administration & dosage
  • Indoles / adverse effects*
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / pathology
  • Magnetic Resonance Imaging
  • Middle Aged
  • Posterior Leukoencephalopathy Syndrome / chemically induced*
  • Posterior Leukoencephalopathy Syndrome / complications
  • Posterior Leukoencephalopathy Syndrome / diagnosis*
  • Posterior Leukoencephalopathy Syndrome / pathology
  • Pyrroles / administration & dosage
  • Pyrroles / adverse effects*
  • Seizures / etiology
  • Sunitinib

Substances

  • Angiogenesis Inhibitors
  • Indoles
  • Pyrroles
  • Sunitinib